Samuel L. Barker's most recent trade in Lexicon Pharmaceuticals Inc was a trade of 103,806 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 103,806 | 103,806 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 89,312 | 89,312 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 36,810 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 36,810 | 124,459 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 87,649 (0%) | 0% | 0 | Common Stock | |
| Cyclacel Pharmaceuticals Inc | Samuel L. Barker | Director | 30 Jun 2023 | 42,438 | 42,438 | - | - | Stock Option (right to buy) | ||
| Cyclacel Pharmaceuticals Inc | Samuel L. Barker | Director | 30 Jun 2023 | 21,219 | 40,415 (0%) | 0% | 0 | Common Stock | ||
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 79,617 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Cyclacel Pharmaceuticals Inc | Samuel L. Barker | Director | 14 Jun 2022 | 31,645 | 31,645 | - | - | Stock Option (right to buy) | ||
| Cyclacel Pharmaceuticals Inc | Samuel L. Barker | Director | 14 Jun 2022 | 15,822 | 19,196 (0%) | 0% | 0 | Common Stock | ||
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 70,315 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Cyclacel Pharmaceuticals Inc | Samuel L. Barker | Director | 30 Nov 2021 | 12 | 3,374 (0%) | 0% | 3.6 | 43 | Common Stock | |
| Cyclacel Pharmaceuticals Inc | Samuel L. Barker | Director | 24 Aug 2021 | 1,000 | 3,386 (0%) | 0% | 5 | 5,000 | Common Stock | |
| Cyclacel Pharmaceuticals Inc | Samuel L. Barker | Director | 15 Jun 2021 | 4,748 | 4,748 | - | - | Stock Option (right to buy) | ||
| Cyclacel Pharmaceuticals Inc | Samuel L. Barker | Director | 15 Jun 2021 | 2,374 | 2,386 (0%) | 0% | 0 | Common Stock | ||
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 66,291 (0%) | 0% | 0 | Common Stock |